Beam Therapeutics (BEAM) Capital Leases (2019 - 2023)

Beam Therapeutics (BEAM) has reported Capital Leases for 5 consecutive years, with $304000.0 the latest figure, recorded in Q3 2023.

• In Q3 2023, Capital Leases fell 78.1% year-over-year to $304000.0; the TTM figure through Sep 2023 stood at $304000.0 (down 78.1% YoY), while the FY2022 annual figure was $1.2 million, down 61.62% from the prior year.
• Capital Leases slipped to $304000.0 in Q3 2023 per BEAM's latest filing, from $875000.0 in the prior quarter.
• Across five years, Capital Leases topped out at $5.3 million in Q1 2020 and bottomed at $304000.0 in Q3 2023.
• Historically, Capital Leases has averaged $3.0 million across 5 years, with a median of $3.3 million in 2021.
• Annual changes were most pronounced in 2020 — Capital Leases advanced 20.02% — and 2023, when it plunged 78.1%.
• Beam Therapeutics' Capital Leases stood at $4.4 million in 2019, then increased by 20.02% to $5.3 million in 2020, then plunged by 43.2% to $3.0 million in 2021, then tumbled by 61.62% to $1.2 million in 2022, then sank by 73.66% to $304000.0 in 2023.
• Business Quant data shows BEAM's Capital Leases at $304000.0 in Q3 2023, $875000.0 in Q2 2023, and $983000.0 in Q1 2023.